Adenosine A2A receptor dysfunction correlates with age at onset anticipation in blood platelets of subjects with Huntington's disease

American Journal of Medical Genetics - Neuropsychiatric Genetics

Volumn 139 B, Issue 1, 2005, Pages 101-105

  Maglione, V ^a   Giallonardo, P ^a   Cannella, M ^a   Martino, T ^a   Frati, L ^a,b   Squitieri, F ^a  

^a IRCCS NEUROMED   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Adenosine A2A receptor dysfunction; Age at onset anticipation; Genetic analysis of siblings; Genetics of Huntington's disease

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE A2A RECEPTOR; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISSOCIATION CONSTANT; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; MALE; ONSET AGE; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR DENSITY; SIBLING; THROMBOCYTE; ADOLESCENT; AGED; BLOOD; GENETIC MARKER; GENETICS; METABOLISM; MIDDLE AGED; PEDIGREE; PHYSIOLOGY; PROTEIN BINDING; TRINUCLEOTIDE REPEAT;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; ANTICIPATION, GENETIC; BLOOD PLATELETS; FEMALE; GENETIC MARKERS; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; PEDIGREE; PROTEIN BINDING; RECEPTOR, ADENOSINE A2A; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 27644446045     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30223     Document Type: Article

References (20)

1. Ashizawa T, Conneally PM. 1999. Repeats may not be everything in anticipation. Neurology 53:1164-1165.
2. Cannella M, Gellera C, Maglione V, Giallonardo P, Cislaghi G, Muglia M, Quattrone A, Pierelli F, Di Donato S, Squitieri F. 2004. The gender effect in juvenile Huntington disease patients of Italian origin. Am J Med Genet B Neuropsychiatr Genet 1258:92-98.
3. Cha JH. 2000. Transcriptional dysregulation in Huntington's disease. Trends Neurosci 23:387-392.
4. Cha JH, Frey AS, Alsdorf SA, Kerner JA, Kosinski CM, Mangiarini L, Penney JB Jr, Davies SW, Bates GP, Young AB. 1999. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos Trans R Soc Lond B Biol Sci 354:981-989.
5. Chiang MC, Lee YC, Huang CL, Chern Y. 2005. CREB contributes to suppression of the A2A adenosine receptor promoter by mutant Huntington with expanded polyglutamine residues. J Biol Chem 280:14331-14340.
6. Dreux C, Launay JM. 1985. Blood platelets: Neuronal model in psychiatric disorders. Encephale 11:57-64.
7. Ferre S, O'Connor WT, Fuxe K, Ungerstedt U. 1993. The striopallidal neuron: A main locus for adenosine-dopamine interactions in the brain. J Neurosci 13:5402-5406.
8. Glass M, Dragunow M, Faull RL. 2000. The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine, and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97:505-519.
9. Kennedy L, Shelbourne PF, Dewar D. 2005. Alterations in dopamine and benzodiazepine receptor binding precede overt neuronal pathology in mice modelling early Huntington disease pathogenesis. Brain Res 1039:14-21.
10. Li JL, Hayden MR, Almqvist EW, Brinkman RR, Durr A, Dode C, Morrison PJ, Suchowersky O, Ross CA, Margolis RL, Rosenblatt A, Gomez-Tortosa E, Cabrero DM, Novelletto A, Frontali M, Nance M, Trent RJ, McCusker E, Jones R, Paulsen JS, Harrison M, Zanko A, Abramson RK, Russ AL, Knowlton B, Djousse L, Mysore JS, Tariot S, Gusella MF, Wheeler VC, Atwood LD, Cupples LA, Saint-Hilaire M, Cha JH, Hersch SM, Koroshetz WJ, Gusella JF, MacDonald ME, Myers RH. 2003. A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. Am J Hum Genet 73:682-687.
11. Mangano RM, Schwarcz R. 1981. The human platelet as a model for the glutamatergic neuron: Platelet uptake of L-glutamate. J Neurochem 36:1067-1076.
12. Reilmann R, Rolf LH, Lange HW. 1994. Huntington's disease: The neuro-excitotoxin aspartate is increased in platelets and decreased in plasma. J Neurol Sci 127:48-53.
13. Squitieri F, Sabbadini G, Mandich P, Gellera C, Di Maria E, Bellone E, Castellotti B, Nargi E, de Grazia U, Frontali M, Novelletto A. 2000a. Family and molecular data for a fine analysis of age at onset in Huntington disease. Am J Med Genet A 95:366-373.
14. Squitieri F, Berardelli A, Nargi E, Castellotti B, Mariotti C, Cannella M, Lavitrano ML, de Grazia U, Gellera C, Ruggieri S. 2000b. Atypical movement disorders in the early stages of Huntington's disease: Clinical and genetic analysis. Clin Genet 58:50-56.
15. Strong TV, Tagle DA, Valdes JM, Elmer LW, Boehm K, Swaroop M, Kaatz KW, Collins FS, Albin RL. 1993. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat Genet 5:259-265.
16. n repeat length is the sex of the affected parent. Hum Mol Genet 2:1535-1540.
17. 3H]-CGS 21680 binding. Br J Pharmacol 117:1693-1701.
18. Varani K, Rigamonti D, Sipione S, Camurri A, Borea PA, Cattabeni F, Abbracchio MP, Cattaneo E. 2001. Aberrant amplification of A(2A) receptor signaling in striatal cells expressing mutant Huntington. FASEB J 15:1245-1247.
19. Varani K, Abbracchio MP, Cannella M, Cislaghi G, Giallonardo P, Mariotti C, Cattabriga E, Cattabeni F, Borea PA, Squitieri F, Cattaneo E. 2003. Aberrant A2A receptor function in peripheral blood cells in Huntington's disease. FASEB J 17:2148-2150.
20. Wexler NS, Lorimer J, Porter J, U.S.-Venezuela Collaborative Research Project. 2004. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci 101:3498-3503.